McGill's Professor Bartha Maria Knoppers to co-lead the work package on ethics and interoperability.
On March 15, Canada’s three federal research funding agencies—the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC) launched the Tri-Agency Research Data Management Policy (“RDM Policy”).
McGill’s researchers are increasingly reliant on the production, sharing and management of large amounts of data to generate knowledge. Regardless of the research discipline, scope and scale of the research activities, or technological proficiency, access to digital infrastructure has become a fundamental need. As a result, there is a growing need at the University that researchers are supported in the three pillars of digital research infrastructure: Research Data Management (RDM), Advanced Research Computing (ARC), and Research Software (RS).
Microplastics are tiny pieces of plastic that are microscopic and up to 5 millimetres in size. McGill research project aims to provide an understanding of how these contaminants end up in Canadian aquatic environments and what impacts they have.
Experts across Canada, including researchers at McGill, are working to understand the impact of COVID-19 virus variants of concern on the health of Canadians and our public health measures. Today, the Honourable Patty Hajdu, Minister of Health, announced an investment of $14.3 million from the Government of Canada, through the Canadian Institutes of Health Research (CIHR), to support new research on the COVID-19 virus variants.
A Made-in-Canada data solution to support the Government of Canada Variants of Concern Strategy
NeuroSphere, McGill’s neuroscience innovation accelerator, is pleased to announce the 12 award recipients from its second Ignite Grant Competition.
Turn your scientific idea into a viable startup through the 2021 McGill Neuroscience LEAN Startup Program!
NeuroSphere, the McGill platform dedicated to innovation and partnership in neuroscience research, is proud to award scholarships for the Life Sciences Entrepreneurship Development Program (LSEDP) to Theresa Degenha
After nearly 5 years as McGill’s Associate Vice-Principal, Research and Innovation (AVP-RI), Professor Nancy Ross is leaving McGill to join Queen’s University as Vice-Principal, Research. She will begin her appointment on August 1, 2021.
For Ross, her upcoming journey to Kingston will be a homecoming. Ross received her Bachelor and Master of Arts degrees from Queen’s. She also holds a Ph.D. from McMaster University.
McGill University announced today it has concluded an agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to provide McGill-based startup companies with the benefit of CCRM’s market-leading business intelligence and experience.
Read the story in the McGill Reporter
Read the McGill news release
Funded Projects:
SecureData4Health
McGill team lead: Guillaume Bourque, Faculty of Medicine and Health Sciences.
$4.67M from Brain Canada will help probe the brain’s mysteries and create international research links
Research at The Neuro’s McConnell Brain Imaging Centre (BIC) of McGill University will receive a major boost thanks to a $4.67M grant from Brain Canada’s Platform Support Grant (PSG) program.
Research and Innovation and IT Services are pleased to welcome Marc Rousseau to the role of Director, Research Software / Directeur du Logiciel de Recherche. In this new role, Rousseau provides support and advice to the McGill research community on software, from grant applications to the implementation of research activities. He will also lead the development of the McGill Digital Research Services team, which will assist researchers in all fields of study with resources and tools in research data management (RDM), research software (RS) and advanced research computing (ARC).
TORONTO, Feb. 4, 2021 /CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with McGill University for the exclusive use of Dr. Gabriella Gobbi's groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.